Finally, Some Good News in the Fight Against Lyme Disease

Key Points:

• Pfizer and Valneva announced that their Lyme disease vaccine candidate, PF-07307405, showed over 70% effectiveness in a late-stage clinical trial, though the statistical confidence in the data was lower than expected.
• The vaccine works uniquely by producing antibodies against the outer surface protein A (OspA) of Borrelia burgdorferi, which are ingested by ticks during feeding and prevent the bacteria from leaving the tick, thereby blocking infection.
• The Phase III VALOR trial involved nearly 10,000 participants at high risk for Lyme disease across North America and Europe, with four doses administered over two years and follow-up through peak Lyme seasons.
• Although the primary analysis confidence interval ranged from 15.8% to 93.5%, below the target lower bound of 20%, a secondary analysis showed a confidence interval above 20%, prompting the companies to plan submission for FDA approval.
• Experts note that Lyme disease is increasing in prevalence, and a safe, effective vaccine would be a significant advancement in prevention, especially for outdoor enthusiasts and residents in endemic areas.